Prediction of axillary lymph node status in male breast carcinoma

Vaysse, Charlotte; Sroussi, J.; Mallon, Peter; Féron, Jean-Guillaume; Rivain, A L; Ngô, Charlotte; Bélichard, C.; Lasry, S.; Pierga, J. Y.; Couturaud, Benoît; Fitoussi, A.; Laki, Fatima; Fourchotte, Virginie; Alran, S.; Kirova, Youlia; Vincent‐Salomon, Anne; Sastre-Garau, Xavier; Sigal‐Zafrani, Brigitte; Rouzier, Roman; Reyal, F.

doi:10.1093/annonc/mds283

Cited by 14 publications

(15 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was indicated that the most important prognostic factor for male breast cancer patients is the presence of metastases in the lymph nodes [21,27,31,34]. Our observations are similar.…”

Section: Discussionsupporting

confidence: 86%

“…We observed lymph nodes involvement in 17 out of the 32 patients (53.1%). Other authors reported lymph nodes metastases in 46-50% of the male patients with breast cancer [25,27,34]. In our study the presence of lymph node metastases significantly decreases cancer-free survival rates.…”

Section: Discussionsupporting

confidence: 56%

“…In the literature the size of the analysed groups ranges from 31 to 118 patients, studied over a periods from 14 to 47 years [15,16,20,21,27,28,29,31,33]. The number of male patients treated for breast carcinoma at the Institute of Oncology in Cracow is similar.…”

Section: Discussionmentioning

confidence: 99%

“…Male breast cancer has a higher (over 90%) hormone receptor expression and, as a consequence, reacts more effectively to endocrine therapy [6,16,17,19,22,23,24,25,26,27].…”

Section: Abstract: Male Breast Cancer Basal Markers Mesenchymal Mamentioning

confidence: 99%

“…Besides, the prognosis for male breast cancer is worse [5,18,20,21]. A study by Baojiang et al of 5-year survival rates of patients suffering from male breast carcinoma and female breast carcinoma produced the following results: 61.2% and 68.7% (DFS), and 75.% and 82.9% (OS), respectively [20].Male breast cancer has a higher (over 90%) hormone receptor expression and, as a consequence, reacts more effectively to endocrine therapy [6,16,17,19,22,23,24,25,26,27].The treatment of male breast carcinoma is based on standard methods, more specifically surgical procedures [6, 21, 25, …”

mentioning

confidence: 99%

See 4 more Smart Citations

The biological markers and results of treatment in male breast cancer patients. The Cracow experience.

Sas-Korczyńska¹,

Niemiec²,

Harazin-Lechowska³

et al. 2014

neo

View full text Add to dashboard Cite

Male breast cancer is a rare form of carcinoma with an incidence rate of approximately 0.5-1% compared with cases of breast carcinoma as a whole. Male breast cancer reacts effectively to endocrine therapy because of a high frequency of hormone receptor expression.The aim of the present study was the assessment of correlations between stage, grade, expression of steroid receptors, basal/mesenchymal markers and proliferation index, as well as analysis of the impact of the above-mentioned parameters on overall (OS) and disease-free survival (DFS) in the group of 32 male breast cancer patients, treated at the Centre of Oncology in Cracow.We showed the significant positive correlation between MIB-1 LI and tumor stage, and hormone receptors (ER or PgR) immunonegativity, and expression of EGFR, vimentin (p<0.05) and P-cadherin (the last at statistical border). The presence of any of basal or masenchymal markers correlated with a more advanced tumor stage. Moreover tumors without vimentin expression were characterised by lower MIB-1 LI and were more frequently EGFR immunonegative.We found that hormone receptor negativity, vimentin immunopositivity and high MIB-1 LI are significant independent indicators of poor OS and DFS for male breast cancer patients (p<0.05). Key words: male breast cancer, basal markers, mesenchymal markers, nodal status, hormonal receptorsMale breast cancer is a rare form of carcinoma with an incidence rate of approximately 0.5-1% compared with cases of breast carcinoma as a whole [1,2,3,4]. Its peak incidence is noted in the seventh decade of life [5,6,7]. The most significant risk factors are an increased concentration of estrogen and obesity, that are a result of estrogen overproduction, impaired metabolism, and disturbances in the concentration of estrogen and androgen (i.e. in Klinefelter's syndrome) as well as the use of estrogenes in prostate cancer treatment [6,8,9,10,11]. Other factors include alcoholism, liver cirrhosis, the presence of hereditary BRCA1 and BRCA2 gene mutations and exposure to ionizing radiation, the electromagnetic field and increased temperature [6,8,9,12,13,14,15,16,17].According to Anderson et al., male breast cancer is characterised by similar biological factors to those present in the female variant of the cancer [18]. However, these tumors are diagnosed in more advanced stages of the disease, are characterised by higher degree of differentiation (more frequently G1, G2 grade) and a lower mitotic index in comparison to female breast cancer [5,19]. There are also differences in the frequency of the expression of hormone receptors and growth factor receptors [19,20]. Besides, the prognosis for male breast cancer is worse [5,18,20,21]. A study by Baojiang et al. of 5-year survival rates of patients suffering from male breast carcinoma and female breast carcinoma produced the following results: 61.2% and 68.7% (DFS), and 75.% and 82.9% (OS), respectively [20].Male breast cancer has a higher (over 90%) hormone receptor expression and, as a consequence, reacts more effect...

show abstract

“…It was indicated that the most important prognostic factor for male breast cancer patients is the presence of metastases in the lymph nodes [21,27,31,34]. Our observations are similar.…”

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 56%

Section: Discussionmentioning

confidence: 99%

“…Male breast cancer has a higher (over 90%) hormone receptor expression and, as a consequence, reacts more effectively to endocrine therapy [6,16,17,19,22,23,24,25,26,27].…”

Section: Abstract: Male Breast Cancer Basal Markers Mesenchymal Mamentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

The biological markers and results of treatment in male breast cancer patients. The Cracow experience.

Sas-Korczyńska¹,

Niemiec²,

Harazin-Lechowska³

et al. 2014

neo

View full text Add to dashboard Cite

show abstract

Surgical options for male breast cancer

Fentiman

2018

Breast Cancer Res Treat

View full text Add to dashboard Cite

BackgroundMale breast cancer (MBC) is a rare disease for which no randomised controlled trials (RCT) have been conducted to determine optimal surgical management. The available data have been reviewed to identify reasonable options and reveal areas in need of investigation.MethodsAll published series on the surgical management of MBC have been reviewed to determine approaches to treatment of the primary, the breast and the axilla together with the psychological sequelae of surgery.FindingsMastectomy is still the major surgical offer but a convincing case can be made for the use of neoadjuvant endocrine treatment in order to facilitate breast conserving surgery. Sentinel node biopsy has been successfully used for staging MBC although nomograms for prediction of nodal status are inadequately calibrated. There are psychological sequelae of mastectomy in males and as yet no evidence that the needs of those with MBC are being met.ConclusionsCollaborative studies are required so that men can participate in meaningful RCTs to provide an evidence-based rational foundation for the surgery of MBC.

show abstract

A contemporary review of male breast cancer: current evidence and unanswered questions

Leon‐Ferre

Giridhar

Hieken

et al. 2018

Cancer Metastasis Rev

View full text Add to dashboard Cite

Male breast cancer is rare, accounting for 1% of all breast cancer diagnoses in the USA. Because of its rarity, most major breast cancer trials have included only female patients. This has resulted in limited prospective data to guide the clinical management of men with breast cancer. As a result, treatment decisions are typically extrapolated from data generated in female patients. This approach may be suboptimal, particularly considering the differing hormonal milieus between men and women with respect to both breast cancer development and treatment. Herein, we summarize current knowledge of the biology and clinicopathology of male breast cancer and review current approaches to locoregional and systemic management of this rare disease.

show abstract

Prediction of axillary lymph node status in male breast carcinoma

Abstract: Multi-variate models designed to predict axillary lymph node metastases for female BC were not effective in our male BC series. Our results may be explained by (i) small sample size (ii) different biological determinants influencing axillary metastasis in male BC compared with female BC.

Cited by 14 publications

References 43 publications

The biological markers and results of treatment in male breast cancer patients. The Cracow experience.

The biological markers and results of treatment in male breast cancer patients. The Cracow experience.

Surgical options for male breast cancer

A contemporary review of male breast cancer: current evidence and unanswered questions

Contact Info

Product

Resources

About